ERYP Erytech Pharma S.A.

6.67
0  0%
Previous Close 6.67
Open
Price To Book 0.73
Market Cap 119,643,358
Shares 17,937,535
Volume 1
Short Ratio
Av. Daily Volume 1,122

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial completed.
Hydro-Lido
Hemorrhoids
Phase 3 enrolment has commenced - noted September 20, 2018.
Eryaspase (GRASPA)
Pancreatic cancer
Upcoming meeting with FDA to discuss next steps.
Eryaspase (GRASPA)
Acute lymphoblastic leukemia (ALL) - front line
Phase 2 dosing has commenced - noted June 26, 2019.
Eryaspase (GRASPA) - TRYbeCA2
Triple-Negative Breast Cancer (TNBC)